[Concept for routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV)]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005086
Original Title: Brexucabtagen Autoleucel (rezidivierte oder refraktäre B-Zell-Vorläufer ALL)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia
  • Lymphoma
  • Immunotherapy, Adoptive
  • Receptors, Chimeric Antigen
  • Antineoplastic Agents, Immunological
  • Registries
  • Brexucabtagene Autoleucel
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Registries
  • Benefit Assessment
  • Concept
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.